FUTURE PROOF HEALTHCARE

A sustainable healthcare for a new generation

Company presentation Life Science Investor Conference – 2023/04/19

Jonas Jarvius, CEO & President Anders Lundin CFO, IR





Disclaimer

THIS PERESNTATION AND ITS CONTENTS ARE CONFIDENTIAL AND ARE NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION IS UNLAWFUL.

This presentation has been prepared and issued by and is the sole responsibility of Q-linea AB (the "Company") and is being furnished to each recipient solely for its own information and in connection with the preliminary discussions in relation to the Company. For the purposes of this disclaimer, "presentation" means these slides, their contents or any part of them, any oral presentation, any question or answer session and any written or oral materials discussed or distributed during the presentation meeting.

This presentation may not be copied, passed on, reproduced or redistributed, directly, in whole or in part, or disclosed by any recipient, to any other person (whether within or outside such person's organisation or firm), and it may not be published anywhere, in whole or in part, for any purpose or under any circumstances. It is expressly forbidden to disclose the information in this presentation to any other person.

This presentation reflects the situation/information as of the date hereof and has not been independently verified and no representation or warranty, express or implied, is given by or on behalf of the Company, Carnegie Investment Bank AB (publ) (the "Manager"), any of their respective affiliates or any of such persons' respective directors, officers, employees, agents, affiliates or advisers as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation and no responsibility or liability is assumed by any such persons for such information or opinions of nor any errors, omissions or mistatements contained herein.

This presentation contains summary information only and does not purport to be comprehensive and is not intended to be (and should not be used as) the sole basis of any analysis or other evaluation. The information set out in this presentation may be subject to updates, revisions, verifications and amendments without notice and the information may thus change materially. None of the Company, the Manager, any of their respective affiliates or any of such persons' respective directors, officers, employees, agents, affiliates or advisers is under an obligation to update or keep current the information directors is presentation or to provide the recipient with access to any additional information that may arise in connection with it, and any opinions expressed in this presentation are subject to change without notice and none of them will have any lability whatsoever (in negligence or otherwise) for any loss whatsoever arising from any use of this presentation or otherwise arising in connection with this presentation.

This presentation does not constitute or form part of, and should not be construed as, any offer, invitation, solicitation or recommendation to purchase, sell or subscribe for any securities in any jurisdiction and neither the issue of the information nor anything contained herein shall form the basis of or be relied upon in connection with, or act as an inducement to enter into, any investment activity. This presentation does not purport to contain all of the information that may be required to evaluate any investment in the Company or any of its securities and should not be relied upon to form the basis of, or be relied on in connection with, any contract or commitment or investment decision whatsoever.

This presentation is intended to present background information on the Company, its business and the industry in which it operates and is not intended to provide complete disclosure upon which an investment decision could be made. The merit and suitability of an investment in the Company should be independently evaluated and any person considering such an investment in the Company is advised to obtain independent advice as to the legal, tax, intellectual property, accounting, financial, credit and other related advice prior to making an investment. The Company has not decided whether to proceed with any transaction.

To the extent available and unless otherwise explicitly stated, the industry and market data contained in this presentation has come from official or third-party sources. Third party industry publications, studies and surveys generally state that the data contained therein has been obtained from sources believed to be reliable, but that there is no guarantee of the accuracy or completeness of such data. While the Company believes that each of these publications, studies and surveys has been prepared by a reputable source, the Company has not independently verified the data contained therein. In addition, certain of the industry and market data contained in this presentation originates from the Company's own internal research and estimates based on the knowledge and experience of the Company's management in the market in which the Company operates. While the Company believes that such research and estimates are reasonable and reliable, they, and their underlying methodology and assumptions, have not been verified by any independent source for accuracy or completeness and are subject to change without notice. Accordingly, undue reliance should not be placed on any of the industry or market data contained in this presentation.

This presentation is only addressed to and directed at persons in member states of the European Economic Area ("EEA") who are qualified investors within the meaning of Article 2(1)(e) of the Prospectus Directive (Directive 2003/71/EC), as amended ("Qualified Investors"). In addition, in the UK, this presentation is addressed to and directed only at Qualified Investors who are persons who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "Order"), are persons who are high net worth entities falling within Article 49(2)(a) to (d) of the Order or are persons to whom it may otherwise lawfully be communicated (all such persons being referred to as "relevant persons").

This presentation must not be acted on or relied on in the UK by persons who are not relevant persons and in any member state of the EEA other than the UK by persons who are not Qualified Investors. Any investment or investment activity to which this presentation relates is available only to relevant persons in the UK and Qualified Investors in any member state of the EEA other than the UK and will be engaged in only with such persons.

This presentation and the information contained herein are not an offer of securities for sale and are not for publication or distribution in the US or to persons in the US (within the meaning of Regulation S under the US Securities Act of 1933, as amended (the "Securities Act")), or any other jurisdiction where such distribution or offer is unlawful, except to qualified institutional buyers ("QIBS") as defined in Rule 144A under the Securities Act ("Rule 144A"). The Company does not intend to conduct a public offering of any securities of the Company have not been and will not be registered under the Securities Act and may not be offered or sold in the US without registration except to QIBs in reliance on Rule 144A or another exemption from, or in transactions not subject to, the registration requirements of the Securities Act. Subject to certain limited exceptions, neither this presentation nor any copy of it may be taken, transmitted or distributed, directly or indirectly, into the US, its territories or possessions. Any failure to comply with the foregoing restrictions may constitute a violation of US securities laws.

Certain statements in this presentation may constitute forward-looking statements, beliefs or opinions, including statements with respect to the Company's business, financial condition and results of operations. These statements reflect the Company's business, financial condition and results of operations. These statements reflect the Company's business, financial condition and results of operations. These statements reflect the Company's business, financial condition and results of operations. These statements reflect the Company's business, financial condition and results of operations. These statements reflect the Company's business, financial condition and results of operations. These statements and thure business strategies and the environment the Company will operate in and are subject to risks and uncertainties that may cause actual results to differ materially different from those expressed or implied by such forward looking statements. Many of these risks and uncertainties reflect the Company's ability to control or estimate precisely, such as future market conditions, currency fluctuations, the behaviour of other market participants, the actions of regulators and other factors such as the Company's ability to continue to obtain financing to meet its liquidity needs, changes in the political, social and regulatory framework in which the Company operates or in economic or technological trends or conditions. As a result, you are cautioned not to place undue reliance on such forward-looking statements. Past performance should not be taken as an indication or guarante of future results, and no representation or warranty, express or implied, is made regarding future performance of such market participants, the actions of such persention or varranty, express or implied, is statements speak only as of their date. Forward-looking statements speak only as of their market participants, the respective directors, officers, employees, agents, affiliates or advisers expressly disclaim any obligation or undertaking t

The Manager is authorised by the Swedish Financial Supervisory Authority (Sw. Finansinspektionen) and is acting exclusively for the Company and no one else in connection with this presentation or any future transaction in connection with it. The Manager will not regard any other person (whether or not a recipient of this presentation) as a client and will not be responsible to anyone other than the Company for providing the protections afforded to their respective clients nor for the giving of advice in relation to any transaction, matter or arrangement referred to in this presentation.

THIS PRESENTATION IS BEING DELIVERED IN CONNECTION WITH A PROPOSED MEETING WITH THE COMPANY AND NO COPY OF THE PRESENTATION WILL BE LEFT BEHIND AFTER THE MEETING. BY ATTENDING THE MEETING WHERE THIS PRESENTATION IS

MADE, YOU AGREE TO BE BOUND BY THE FOREGOING LIMITATIONS AND TO MAINTAIN ABSOLUTE CONFIDENTIALITY REGARDING THE INFORMATION DISCLOSED IN THIS PRESENTATION.

Q-LINEA

Q-linea highlights

Headquarters, Marketing and demo lab, Consumable production in Uppsala



Q-linea is developing disruptive solutions for faster infectious disease diagnostics, first product targeting sepsis

Planning & implementation of new commercialisation strategy

Signed distribution agreements for the UK & Polish market Building commercial organisation in the USA and Italy Actively participating in several customer evaluations

Progress toward US market

Additional testing ongoing for the 510(k) application

Goal is to submit data in June

Q-linea participates in several customer driven evaluation ASTar in Europe

Lead product ASTar®



Q-linea facilities & staff

Headquarter, management, finance, HR & R&D





Commercial, training & demo

























Unique technology enables disruptive expansion pipeline & commercial opportunities



Q-linea technology is covered by 24 patent families

O-LINE

5 Source Company data. * In development. Podler is a registrated trademark within EU

Urgent need for improved infectious disease diagnostics

Sepsis is the most common cause of death in our hospitals

More common than lung + prostate + breast-cancer **combined** Accounts for approximate 30% of all deaths in the hospital Most expensive condition to treat in the US. >27B USD¹)

Time to correct treatment is critical!

7.6% decrease of survival rate for every hour of delay of effective therapy²⁾



Source: 1). http://www.hcup-us.ahrq.gov /reports/ statbriefs/sb204-Most-Expensive-Hospital-Conditions.pdf. 2). Kumar et al, Crit Care Med. 2006 Jun;34(6):1589-96

Improved diagnostics needed today and for future generations

Antimicrobial resistance is dramatically increasing

Today treatment of infections is difficult due to bacterial resistance

Treatment is based on assessments (empiric) not on diagnostics Many treatments are ineffectual or unnecessary

> Has been presented as "Greatest threat to mankind"

Source: 1). http://www.hcup-us.ahrq.gov /reports/ statbriefs/sb204-Most-Expensive-Hospital-Conditions.pdf. 2). Kumar et al, Crit Care Med. 2006 Jun;34(6):1589-96



ASTar – designed to save lifetimes

Developed together with our future customers




• High reproducibility



ASTar classified as a breakthrough device by the FDA

Large addressable market for rapid AST diagnostics instruments


ASTar has several potential target markets



1) Blood from positive blood culture. Source: Management account on estimated annual addressable market volume, US + CE + APAC, 2) Management account on estimated annual addressable market volume, US + CE



Up to 48 hours faster actionable results




Time to Actionable results is what matters for septic patients



ASTar makes a difference in patient outcome

Patient-case from first commercial evaluation in Sweden



Health economic benefits of faster 24 hours faster diagnostics

Lower mortality

Less pressure for resistance and superinfections

Up to 40% lower mortality rates¹⁾ Up to 25% reduction of C. *difficile* infections²⁾ **Cost savings**

~\$2,500 – \$20,000 cost savings per patient³⁾

ASTar can provide **up to 48 hours** faster diagnostics

Source: 1) Patel et al, J Clin Microbiol. 2017 Jan; 55(1): 60–67., ECCMID 2017, poster OS1033, Andreassen et al. Cost-effectiveness of MALDI-TOF and rapid antimicrobial susceptibility testing for high-risk patients, Huang et al. Clin Infect Dis. 2013 Nov; 57(9): 1237-45. 2) Fridkin et al, MMWR, 2014;63(9), 194-200. 3) Perez et al, Arch Pathol Lan Med 137:1247-1254, 2013, Perez et al J Infect. 2014 Sep;69(3):216-25, 2014, Bauer et al Clin Infect Dis 51:1074-1080, 2010.) Patel et al, J Clin Microbiol. 2017 Jan; 55(1): 60–67.




ASTar performance is strong and it is easy to use

Evaluation of commercial systems for rapid antimicrobial susceptibility testing (rAST) of positive blood cultures: Comparison of susceptibility results

View Sheffield Hospital's scientific poster presentation from ECCMID 2022, featuring the ASTar System.

ASTar's panel covered 95,4% of all organisms included in the study.



Robert Price, Senior Biomedical Scientist, Whiston Hospital, UK



Large multicentre evaluation in Germany and UK.

Covered 500 ASTar determinations on routine clinical samples. Compared against both Sensititre[™],Vitek[®] and multipoint.

ASTar's panel covered 98,7% of all organisms included in the study.

Essential agreement (EA) >96,6%.



Source: Company information.

ASTar enables anyone at the lab to load samples anytime

Click "start" Scan barcode Add sample Load AST disc 1 mL 5 Add sample User testimonial; barcode How ASTar has helped save time in the lab Listen to Ehsan Ghaderi, Head of Dept, and Sofia Persson, Consultant Click "Start run" Physician, Bacteriology, Uppsala University Hospital, Sweden Q-LINE

User friendly

& 24/7 availability

Source: Company information and webpage

High throughput and flexible solution

Our ambition was the most user friendly and capable system

High throughput & flexible



Fully automatic Semi automatic





Consumables stored at room temp and a small insert at -20°C.

Compatible with small and large (e.g. urine) sample volumes, and to run isolates separately

Up to 12 patient samples in parallel






Excellent and <u>accurate</u> data from the CE-IVD clinical study

Broadest panel enabling actionable results

FDA and ISO requirements ^{1,2)}		
Essential agreement = Same MIC value as reference		
FDA	ISO	Q-LINEA
89.9%	90%	94.7% ³
Categorical agreement = Correct treatment recommendation		
FDA	ISO	Q-LINEA
89.9%	90%	97.6% ³
Reproducibility		
FDA	ISO	Q-LINEA
95%	95%	99.6% ³

The ASTar[®] Instrument and ASTar[®] BC G- Kit offer the **broadest combination of antimicrobials and dilution ranges** in a single analysis for Gram-negative bacteria ⁶. The analysis also **delivers true MIC results.**



Q-LINEA

Source: 1) ISO 20776-2, Clinical laboratory testing and in vitro diagnostic test systems — Susceptibility testing of infectious agents and evaluation of performance of antimicrobial susceptibility test devices: - Part 2: Evaluation of performance of antimicrobial susceptibility test devices 2) Guidance for Industry and FDA Class II Special Controls Guidance Document: Antimicrobial Susceptibility Test (AST) Systems, August 28, 2009, FDA document number 631.3) Company results from CE-IVD clinical study for BC G-, Gram negative antibiotic panel 2020-05-04 6) Based on commercially available systems market overview May 2021

Updated commercialisation strategy – first stage in 2023

Initially focus on key geographies in Europe and East coast in the USA & at the same time manage costs

USA – Q-linea Inc. Most important market due to size and demonstrated to be more mature for rAST than Europe

Pre-FDA evaluations in discussions with two hospitals

Will be approached using internal sales force & regional office Goal is to demonstrate ASTar commercially & Enable a strong ramp-up in 2024

> UK Important market due to size and sepsis awareness

Will be approached using distributor

PRO-LA

Italy – Q-linea S.r.l Important market due to size and demonstrated interest of ASTar

Base for first HEOR study

Will be approached using internal sales force & regional office



Benelux Important market due to market leading KOL's

PK/PD driven antibiotic treatment

Will be approached using internal sales force, but no regional office

Large focus on sepsis in 2023

Will be approached using distributor Q-LINEA

17

Source: Company informatio

Time to actionable result is what matters for septic patients


What if time wasted could be time used?

Equal and better care for everyone

We aim to transform infectious disease diagnostics

Q-LINE.

Up to 48 hours faster actionable results



Time to **Actionable** results is what matters for septic patients



Unique technology enables disruptive expansion pipeline & opportunities

